The non-antidepressant effects of citalopram: a clinician's perspective
Tomas Richter1, Zoltan Paluch2, Stefan Alusik3
1Department of Geriatrics, 1st Faculty of Medicine, Charles University in Prague,, Czech Republic.
Abstract:
The authors present an overview of the most often discussed questions concerning citalopram, i.e. its proven effect on the QT interval and related dose reductions. They discuss citalopram's antiplatelet effect including the most recent data and draw attention to serotonin syndrome as its incidence is still underestimated. They go on to discuss hyponatremia pointing out that this condition may develop even in those taking low doses of citalopram. Finally, the authors provide a brief overview of the latest findings on osteoporosis and the serotonergic mechanism inducing it in individuals treated with a selective serotonin reuptake inhibitor.
More Related Videos
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Anxiolytic Drugs: Benzodiazepines and Buspirone
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
The Placebo Effect
